Table of Contents
Liposome Drug Products
Traditional Drug Delivery Systems (DDS)
Liposomes Represent a DDS That Actually Enters the Central Compartment
Evolution of Liposome Design
Marketed Liposome Products
Proposed Liposome Classification Based on Pharmacologic Behavior
Proposed Liposome Classification (Cont.)
Proposed Liposome Classification (Cont.)
Relative Rates of MPS Clearance
Evolution of IV Therapeutic Liposomes
Liposome Pharmacology: Critical Influences
Critical Influences: Drug Itself
Critical Influences: Liposome Size
Critical Influences: Structural Lipid Matrix
Critical Influences: Surface Properties
Comparison of Liposomal Doxorubicin Products: Myocet Vs. DOXIL
Comparison of Liposomal Doxorubicin Products: Myocet Vs. DOXIL
PPT Slide
Myocet – Pharmaceutical Properties
Myocet – Morphology
Myocet – Product Format
Myocet – Pharmacy Preparation Steps
Myocet – Pharmacy Preparation Steps (Continued)
Why Load Drug in Pharmacy Setting? In Vitro Drug Release – Myocet at 37oC
Myocet Pharmacokinetics
Myocet Pharmacokinetic Parameters
PPT Slide
DOXIL – Pharmaceutical Properties
DOXIL – Product Format
PPT Slide
PPT Slide
PPT Slide
DOXIL In vitro Release at 37oC
DOXIL Pharmacokinetics
Doxil Pharmacokinetic Parameter Estimates (n = 83)
Doxil Stability (Aqueous Suspension, 8oC)
DOXIL Tissue Distribution
Chaotic and Mosaic Vessels in Tumors
Extravasation of Doxil
Pegylated Liposome Extravasation in Angiogenic Blood Vessels
PPT Slide
Serial Gamma Scintigrams of KS Patient after Pegylated Liposomes Containing 111In-DTPA
Gamma Scintigram of Lung Cancer Patient 96 Hours after Pegylated Liposomes Containing 111In-DTPA
Gamma Scintigrams of Patient with T4 Squamous Cell Carcinoma of the Tongue (96 Hours after Pegylated Liposomes Containing 111In-DTPA)
Clinical Dosing Profiles: Myocet Vs. DOXIL
Myocet Vs. DOXIL: Conclusions
Summary
|